DCVax®-Brain and DC vaccines in the treatment of GBM

Expert Opinion on Investigational Drugs

Volumn 18, Issue 4, 2009, Pages 509-519

  Wheeler, Christopher J ^a   Black, Keith L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer vaccine; DCVax Brain; Dendritic cell; Immunotherapy; Tumor antigen; Vaccination

Indexed keywords

CANCER VACCINE; DCVAX BRAIN; DENDRITIC CELL VACCINE; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CANCER IMMUNIZATION; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CONVULSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL THERAPY; FEVER; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PERITUMORAL EDEMA; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR IMMUNITY; VACCINE PRODUCTION; ACTIVE IMMUNIZATION; ANIMAL; BRAIN TUMOR; CHEMISTRY; DENDRITIC CELL; IMMUNOLOGY; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ACTIVE; TREATMENT OUTCOME;

EID: 67649671865     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902841951     Document Type: Review

References (77)

1. DeAngelis LM. Medical progress: brain tumors. N Engl J Med 2001;344:114-123
2. Davis FG, Kupelian V, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-oncol 2001;3:152-158 (Pubitemid 33674106)
3. Curran WJJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:690-691
4. Fine HA, Dear KBG, Loeffler JS. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597 (Pubitemid 23100496)
5. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 2001;55:195-204 (Pubitemid 34134044)
6. Stupp R, Hegi ME. Recent developments in the management of malignant glioma. J Clin Oncol 2003;1091-9118:779-788
7. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762-766 (Pubitemid 23121918)
8. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-198 (Pubitemid 32799739)
9. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382 (Pubitemid 34177445)
10. Dandy WE. Removal of the right cerebral hemishpere for certain tumors with hemiplegia. J Am Med Assoc 1928;90:823-825
11. Burger PC. Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl Neurophysiol 1983;46:180-187 (Pubitemid 14217054)
12. Feun LG, Wallace S, Yung WK, et al. Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv 1984;1:239-245 (Pubitemid 15187877)
13. Kapp JP, Sanford RA. Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors. Neurosurgery 1986;19:779-783 (Pubitemid 17182147)
14. Oldfield EH, Clark WC, Dedrick RL, et al. Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage. Cancer Res 1987;47:1962-1967 (Pubitemid 17056707)
15. Ichikawa T, Tamiya T, Adachi Y, et al. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 2000;7:74-82
16. Diete S, Treuheit T, Dietzmann K, et al. Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma. J Neurooncol 2001;53:47-49 (Pubitemid 32936659)
17. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-182 (Pubitemid 27192179)
18. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990;172:631-640 (Pubitemid 20248404)
19. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nat Med 1995;1:1297-1302
20. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97 (Pubitemid 26028748)
21. Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 1996;93:10399-10404
22. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-561 (Pubitemid 27198656)
23. Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998;161:5516-5524 (Pubitemid 28519115)
24. Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998;78:196-201 (Pubitemid 28443177)
25. Matsui S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 1999;163:184-193 (Pubitemid 29295840)
26. Walker PR, Calzascia T, Schnuriger V, et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol 2000;165:3128-3135 (Pubitemid 30728165)
27. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93 (Pubitemid 24181058)
28. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58 (Pubitemid 26028073)
29. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332 (Pubitemid 28144092)
30. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380 (Pubitemid 27014352)
31. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73-78 (Pubitemid 29011020)
32. Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59 (Pubitemid 29143110)
33. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166:4254-4259 (Pubitemid 32224961)
34. Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777-782 (Pubitemid 29422365)
35. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-336 (Pubitemid 30148627)
36. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001;98:8809-8814 (Pubitemid 32678109)
37. Morse MA, Nair S, Fernandez-Casal M, et al. Peroperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 2000;18:3883-3893
38. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pused dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-847 (Pubitemid 32175145)
39. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001;50:337-344 (Pubitemid 32835343)
40. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-1179 (Pubitemid 37363398)
41. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T cells in patients with malignant glioma. Cancer Res 2004;64:4973-4979 (Pubitemid 38924545)
42. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327 (Pubitemid 28144091)
43. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292-6300
44. Bodey B, Bodey BJ, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 2000;20:2665-2676 (Pubitemid 30614482)
45. Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487-498 (Pubitemid 30457707)
46. Liénard Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol Immunother 2004;4:4 (Pubitemid 40217418)
47. Walker EB, Haley D, Miller W, et al. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res 2004;10:668-680 (Pubitemid 38174007)
48. Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 2001;1:497-510 (Pubitemid 33768665)
49. Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004;53:249-255
50. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008;68:5955-5964
51. Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg 1981;55:32-42 (Pubitemid 11125467)
52. Sampson JH, Archer GE, Bigner DD, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM [abstract 2011]. J Clin Oncol 2008;26:(Suppl):92s
53. Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995;61:765-772
54. Dhodapkar KM, Cirignano B, Chamian F, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 2004;109:893-899 (Pubitemid 38500746)
55. Waziri A, Killory B, Ogden ATR, et al. Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol 2008;180:7673-7680
56. Siesjo P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 1996;19:334-345 (Pubitemid 26398802)
57. Toes REM, van der Voort EIH, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation of dendritic cells. J Immunol 1998;160:4449-4456 (Pubitemid 28217303)
58. Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999;90:1115-1124 (Pubitemid 29241181)
59. Ni HT, Spellman SR, Jean WC, et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001;51:1-9 (Pubitemid 32321895)
60. Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006;55:469-474 (Pubitemid 43076899)
61. Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005;22:175-184 (Pubitemid 40255709)
62. Prins RM, Shu CJ, Radu CG, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 2008;57:1279-1289
63. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11:4160-4167 (Pubitemid 40791581)
64. De Vleeschouwer S, Van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. J Neurosurg 2004;100:492-497 (Pubitemid 38541867)
65. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14:3098-3104
66. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-5525 (Pubitemid 41060828)
67. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004;91:1656-1662 (Pubitemid 39546137)
68. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004;27:452-459 (Pubitemid 39447353)
69. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209-2218 (Pubitemid 30399186)
70. Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neuro-Oncol 2003;64:13-20 (Pubitemid 36992456)
71. Wheeler CJ, Black KL, Liu G, et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 2003;171:4927-4933 (Pubitemid 37310617)
72. Northwest Biotherapeutics DCVaxr-Brain Phase II Clinical Trial. Available from: http://www.nwbio.com/clinical-dcvax-brain.php [last accessed 13 November].
73. Jager E, Ringhoffer M, Karbach J, et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-476 (Pubitemid 26178170)
74. Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiform to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-5326 (Pubitemid 39100466)
75. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-675 (Pubitemid 37328821)
76. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854 (Pubitemid 35231542)
77. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastic melanoma. J Clin Oncol 2005;23:2346-2357 (Pubitemid 46218728)